A Trial to Compare the Efficacy and Safety of Once-weekly Lonapegsomatropin With Placebo and a Daily Somatropin Product in Adults With Growth Hormone Deficiency
Public ClinicalTrials.gov record NCT04615273. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
foresiGHt: A Multicenter, Randomized, Parallel-arm, Placebo-controlled (Double- Blind) and Active-controlled (Open-label) Trial to Compare the Efficacy and Safety of Once-weekly Lonapegsomatropin With Placebo and a Daily Somatropin Product in Adults With Growth Hormone Deficiency
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
A 38-week dosing trial of lonapegsomatropin, a long-acting growth hormone product, administered once-a-week versus placebo-control. A daily somatropin product arm is also included to assist clinical judgement on the trial results. A total of 264 adults (males and females) with growth hormone deficiency were included. Randomization occurred in a 1:1:1 ratio (lonapegsomatropin: placebo: daily somatropin product). This is a global trial conducted in, but not limited to, the United States, Europe, and Asia.
Study identification
- NCT ID
- NCT04615273
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 264 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 23 Years to 80 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 3, 2020 (Actual)
- Primary completion
- Nov 2, 2023 (Actual)
- Completion
- Dec 1, 2023 (Actual)
- Last update posted
- Jul 7, 2026
2020 – 2023
United States locations
- U.S. sites
- 23
- U.S. states
- 16
- U.S. cities
- 21
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Ascendis Pharma Investigational Site | Birmingham | Alabama | 35205 | — |
| Ascendis Pharma Investigational Site | Phoenix | Arizona | 85048 | — |
| Ascendis Pharma Investigational Site | Fresno | California | 93720 | — |
| Ascendis Pharma Investigational Site | Los Angeles | California | 90048 | — |
| Ascendis Pharma Investigational Site | Los Angeles | California | 90095 | — |
| Ascendis Pharma Investigational Site | Palo Alto | California | 94304 | — |
| Ascendis Pharma Investigational Site | Torrance | California | 90509 | — |
| Ascendis Pharma Investigational Site | Chicago | Illinois | 60611 | — |
| Ascendis Pharma Investigational Site | Indianapolis | Indiana | 46202 | — |
| Ascendis Pharma Investigational Site | Boston | Massachusetts | 02114 | — |
| Ascendis Pharma Investigational Site | Dearborn | Michigan | 48126 | — |
| Ascendis Pharma Investigational Site | Rochester | Minnesota | 55905 | — |
| Ascendis Pharma Investigational Site | St Louis | Missouri | 63110 | — |
| Ascendis Pharma Investigational Site | Las Vegas | Nevada | 89148 | — |
| Ascendis Pharma Investigational Site | Reno | Nevada | 89511 | — |
| Ascendis Pharma Investigational Site | New York | New York | 10017 | — |
| Ascendis Pharma Investigational Site | New York | New York | 10021 | — |
| Ascendis Pharma Investigational Site | Morehead City | North Carolina | 28557 | — |
| Ascendis Pharma Investigational Site | Portland | Oregon | 97239 | — |
| Ascendis Pharma Investigational Site | Pittsburgh | Pennsylvania | 15212 | — |
| Ascendis Pharma Investigational Site | Dallas | Texas | 75390 | — |
| Ascendis Pharma Investigational Site | San Antonio | Texas | 78232 | — |
| Ascendis Pharma Investigational Site | Seattle | Washington | 98108 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 90 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04615273, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 7, 2026 · Synced Oct 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04615273 live on ClinicalTrials.gov.